Q3 Earnings Estimate for Rezolute Issued By Wedbush

Key Points

• Wedbush forecasts that Rezolute will report a Q3 2026 earnings estimate of ($0.27) per share, with the stock receiving an Outperform rating and a price target of $12.00.
• The recent quarterly earnings release showed Rezolute missed analysts' expectations with an EPS of ($0.26), which is $0.03 below the consensus estimate.
• Institutional investors own 82.97% of Rezolute's stock, indicating significant institutional confidence, as several firms increased their stakes in the company in the second quarter.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Equities research analysts at Wedbush issued their Q3 2026 earnings per share (EPS) estimates for shares of Rezolute in a research note issued to investors on Thursday, September 18th. Wedbush analyst Y. Zhong anticipates that the company will post earnings of ($0.27) per share for the quarter. Wedbush has a "Outperform" rating and a $12.00 price objective on the stock. The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share. Wedbush also issued estimates for Rezolute's FY2030 earnings at $0.71 EPS.

RZLT has been the topic of several other reports. Maxim Group boosted their price target on shares of Rezolute from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a research note on Wednesday, September 3rd. Guggenheim reissued a "buy" rating and set a $15.00 target price on shares of Rezolute in a research note on Monday. Finally, BTIG Research restated a "buy" rating and set a $17.00 target price on shares of Rezolute in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $14.50.

Rezolute Stock Performance

NASDAQ RZLT traded up $0.44 on Monday, reaching $8.14. 1,082,567 shares of the stock traded hands, compared to its average volume of 1,179,967. The firm's fifty day simple moving average is $6.62 and its 200 day simple moving average is $4.74. Rezolute has a 12 month low of $2.21 and a 12 month high of $8.81.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Wednesday, September 17th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.03).

Institutional Trading of Rezolute

Several hedge funds and other institutional investors have recently modified their holdings of the business. Man Group plc acquired a new position in Rezolute during the fourth quarter valued at $425,000. Cubist Systematic Strategies LLC grew its stake in Rezolute by 335.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 210,581 shares of the company's stock valued at $611,000 after acquiring an additional 162,216 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Rezolute by 9.0% in the 1st quarter. Acadian Asset Management LLC now owns 605,042 shares of the company's stock valued at $1,752,000 after purchasing an additional 50,163 shares during the period. OMERS ADMINISTRATION Corp lifted its position in shares of Rezolute by 56.4% in the first quarter. OMERS ADMINISTRATION Corp now owns 118,900 shares of the company's stock worth $345,000 after purchasing an additional 42,900 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Rezolute during the first quarter worth approximately $95,000. Institutional investors and hedge funds own 82.97% of the company's stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.